Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Frontline Science: Characterization and regulation of osteoclast precursors following chronic Porphyromonas gingivalis infection.  Journal of Leukocyte Biology.  108:1037-1050. 2020
2020 Frontline Science: Characterization and regulation of osteoclast precursors following chronic Porphyromonas gingivalis infection..  Journal of Leukocyte Biology.  108:1037-1050. 2020
2020 Enhanced dual function of osteoclast precursors following calvarial Porphyromonas gingivalis infection.  Journal of Periodontal Research.  55:410-425. 2020
2019 Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.  Journal of Bone and Mineral Research.  34:1938-1951. 2019
2018 C/EBPα transcription factor is regulated by the RANK cytoplasmic 535IVVY538 motif and stimulates osteoclastogenesis more strongly than c-Fos..  Journal of Biological Chemistry.  293:1480-1492. 2018
2016 CCAAT/enhancer-binding protein α (C/EBPα) is important for osteoclast differentiation and activity.  Journal of Biological Chemistry.  291:16390-16403. 2016
2015 IL-1R/TLR2 through MyD88 divergently modulates osteoclastogenesis through regulation of nuclear factor of activated T cells c1 (NFATc1) and B lymphocyte-induced maturation protein-1 (Blimp1).  Journal of Biological Chemistry.  290:30163-30174. 2015
2015 The IVVY motif and tumor necrosis factor receptor-associated factor (TRAF) sites in the cytoplasmic domain of the receptor activator of nuclear factor κB (RANK) cooperate to induce osteoclastogenesis.  Journal of Biological Chemistry.  290:23738-23750. 2015
2014 RANK-and c-Met-mediated signal network promotes prostate cancer metastatic colonization.  Endocrine-Related Cancer.  21:311-326. 2014
2013 Interleukin-3 plays dual roles in osteoclastogenesis by promoting the development of osteoclast progenitors but inhibiting the osteoclastogenic process.  Biochemical and Biophysical Research Communications.  440:545-550. 2013
2013 Osteoclasts: New Insights..  Bone Research.  1:11-26. 2013
2013 Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.  Cancer Research.  73:672-682. 2013
2013 IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.  BMC Cancer.  13. 2013
2012 Gut mucosal injury in neonates is marked by macrophage infiltration in contrast to pleomorphic infiltrates in adult: Evidence from an animal model 2012
2012 Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.  Journal of Biological Chemistry.  287:15728-15738. 2012
2012 Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.  Journal of Interferon and Cytokine Research.  32:34-45. 2012
2011 Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: A novel mechanism mediating its blockade of osteoclastogenesis.  Journal of Cellular Biochemistry.  112:3385-3392. 2011
2011 Nucleosides accelerate inflammatory osteolysis, acting as distinct innate immune activators.  Journal of Bone and Mineral Research.  26:1913-1925. 2011
2011 TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-κB.  Journal of Biological Chemistry.  286:24159-24169. 2011
2011 A simplified method for the generation of human osteoclasts in vitro.  International Journal of Biochemistry and Molecular Biology.  2:183-189. 2011
2011 APPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner.  Journal of Bone and Mineral Research.  26:1084-1098. 2011
2011 Disorders of bone remodeling.  Annual Review of Pathology: Mechanisms of Disease.  6:121-145. 2011
2011 Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling.  ASSAY and Drug Development Technologies.  9:40-49. 2011
2010 Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.  Cancer Gene Therapy.  17:893-905. 2010
2010 Erratum: Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer (Cancer Gene Therapy (2010) 17 (893-905)).  Cancer Gene Therapy.  17:906. 2010
2010 Receptor activator of NF-κB (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-α (TNF)-mediated osteoclastogenesis.  Journal of Biological Chemistry.  285:37427-37435. 2010
2010 Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.  Expert Opinion on Therapeutic Targets.  14:923-934. 2010
2009 Chemical and biochemical basis of cell-bone matrix interaction in health and disease.  Current Chemical Biology.  3:189-196. 2009
2009 Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATc1 to transactivate the V-ATPase d2 promoter during RANKL-induced osteoclastogenesis.  Journal of Biological Chemistry.  284:14667-14675. 2009
2009 Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis.  Journal of Biological Chemistry.  284:12512-12523. 2009
2008 Phospholipase Cγ2 mediates RANKL-stimulated lymph node organogenesis and osteoclastogenesis.  Journal of Biological Chemistry.  283:29593-29601. 2008
2008 HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE.  Journal of Bone and Mineral Research.  23:1084-1096. 2008
2008 R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression.  FEBS Letters.  582:643-650. 2008
2007 c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages..  Journal of Biological Chemistry.  282:18980-18990. 2007
2006 Development and validation of vectors containing multiple siRNA expression cassettes for maximizing the efficiency of gene silencing.  BMC Biotechnology.  6. 2006
2006 Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators.  Journal of Biological Chemistry.  281:35686-35698. 2006
2006 Regulation of osteoclast function and bone mass by RAGE.  Journal of Experimental Medicine.  203:1067-1080. 2006
2006 High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals.  Journal of Leukocyte Biology.  79:686-695. 2006
2006 A novel receptor activator of NF-κB (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage.  Journal of Biological Chemistry.  281:4678-4690. 2006
2005 Receptor activator of NF-κB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4.  Journal of Biological Chemistry.  280:43064-43072. 2005
2005 Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells.  Journal of Cellular Biochemistry.  96:716-727. 2005
2005 Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis.  Arthritis and Rheumatism.  52:3257-3268. 2005
2005 Erratum: Osteoclastogenesis: The role of calcium and calmodulin (Critical Reviews in Eukaryotic Gene Expession).  Critical Reviews in Eukaryotic Gene Expression.  15. 2005
2005 RANKing intracellular signaling in osteoclasts 2005
2005 Regulatory roles and molecular signaling of TNF family members in osteoclasts.  Gene.  350:1-13. 2005
2005 Osteoclastogenesis: The role of calcium and calmodulin.  Critical Reviews in Eukaryotic Gene Expression.  15:1-13. 2005
2004 Functional identification of three receptor activator of NF-κB cytoplasmic motifs mediating osteoclast differentiation and function.  Journal of Biological Chemistry.  279:54759-54769. 2004
2004 YY1 is involved in RANKL-induced transcription of the tartrate-resistant acid phosphatase gene in osteoclast differentiation.  Gene.  343:117-126. 2004
2004 Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members.  Biochemical Journal.  383:219-225. 2004
2004 Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-β activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2.  Journal of Biological Chemistry.  279:34311-34322. 2004
2004 AZT enhances osteoclastogenesis and bone loss.  AIDS Research and Human Retroviruses.  20:608-620. 2004
2003 Osteoclast Apoptosis: The Role of Fas in Vivo and in Vitro.  Endocrinology.  144:5545-5555. 2003
2003 PYK2 and FAK in osteoclasts.  Frontiers in Bioscience.  8. 2003
2003 The role of calmodulin in the regulation of osteoclastogenesis.  Endocrinology.  144:4536-4543. 2003
2003 Involvement of upstream stimulatory factors 1 and 2 in RANKL-induced transcription of tartrate-resistant acid phosphatase gene during osteoclast differentiation..  Journal of Biological Chemistry.  278:20603-20611. 2003
2003 PYK2 and FAK in osteoclasts..  Frontiers in Bioscience.  8. 2003
2002 Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.  Endocrinology.  143:4868-4874. 2002
2001 Identification of the type II Na+-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice.  BONE.  29:467-476. 2001
2001 A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function..  Journal of Clinical Investigation.  107:1137-1144. 2001
2001 Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression..  Journal of Biological Chemistry.  276:10119-10125. 2001
2000 Transforming growth factor-beta up-regulates the beta 5 integrin subunit expression via Sp1 and Smad signaling..  Journal of Biological Chemistry.  275:36400-36406. 2000
2000 Sp1/Sp3 and PU.1 differentially regulate beta(5) integrin gene expression in macrophages and osteoblasts..  Journal of Biological Chemistry.  275:8331-8340. 2000
2000 Regulation of alphaVbeta3 and alphaVbeta5 integrins by dexamethasone in normal human osteoblastic cells..  Journal of Cellular Biochemistry.  77:265-276. 2000
2000 Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts..  Journal of Clinical Investigation.  105:433-440. 2000
1999 Cloning of the murine beta5 integrin subunit promoter. Identification of a novel sequence mediating granulocyte-macrophage colony-stimulating factor-dependent repression of beta5 integrin gene transcription..  Journal of Biological Chemistry.  274:1366-1374. 1999
1996 Competition for a unique response element mediates retinoic acid inhibition of vitamin D3-stimulated transcription..  Journal of Biological Chemistry.  271:20650-20654. 1996

Chapter

Year Title Altmetric
2014 MetaboLic Bone Disease II.  829-837. 2014
2005 Osteoclast biology.  71-94. 2005

Principal Investigator On

Investigator On

Education And Training

  • Doctor of Philosophy in Zoology / Animal Biology, University of Vermont 1994
  • Bachelor of Science or Mathematics in Biology, Fudan University 1987

    • Full Name

  • Xu Feng